richard hemming, page-47

That insightful analyst (R Hemming) is back with another article today

http://www.businessday.com.au/business/volatile-royalties-often-bitter-pills-for-biotechs-20120429-1xsyk.html

Why he ties PRR to these other royalty based biotechs is a mystery and only confirms his overall personal agenda.

PRR is not the sole focus of the article but here is excerpt:

"This column had the temerity to suggest that Prima's market cap of $256 million might be overdoing it for a company that hasn't got much in the way of clinical evidence and even if everything goes to plan, will not make a profit for at least another four years."